ctDNA-Guided Camizestrant + CDK4/6i Extends PFS in ESR1-Mutated, HR+/HER2– Advanced Breast Cancer

First Look With ASCO Daily News presents Dr. Julie Gralow, ASCO’s chief medical officer, on the results of the SERENA-6 trial, which assessed the clinical utility of ctDNA to detect and treat emerging resistance, ahead of progression, with camizestrant plus a CDK4/6 inhibitor in patients with HR-positive/HER2-negative advanced breast cancer who have ESR1 mutations. This abstract will be presented as LBA4 during the Plenary Session at the 2025 ASCO Annual Meeting. Read the full abstract: https://meetings.asco.org/abstracts-presentations/245971 For more on ASCO25, visit https://dailynews.ascopubs.org/meetings/asco-annual-meeting _Data as of May 19, 2025_

Video Lainnya